Alluvi, previously BI 4744, represents a notable advance in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/